

NCT00461136 Raw comparison:

Summary:
CHIA has 45 criteria while your personal folder has 47 criteria
Total found criteria: 45/45
Total not Found: 0/45
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Male and/or female patients from 30-80 years of    │ Male and/or female patients from 30-80 years of    │
│ age with a diagnosis of Type 2 diabetes (WHO       │ age with a diagnosis of Type 2 diabetes (WHO       │
│ criteria)                                          │ criteria)                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Incipient and established diabetic nephropathy     │ Incipient and established diabetic nephropathy     │
│ (urinary albumin excretion ≥ 100 mg/day but ≤ 2000 │ (urinary albumin excretion ≥ 100 mg/day but ≤ 2000 │
│ mg/day)                                            │ mg/day)                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Glomerular filtration rate (GFR) ≥ 40 ml/min       │ Glomerular filtration rate (GFR) ≥ 40 ml/min       │
│ (estimated using Modification of Diet in Renal     │ (estimated using Modification of Diet in Renal     │
│ Disease (MDRD) formula) in the last 4 months       │ Disease (MDRD) formula) in the last 4 months       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Female patients must be postmenopausal or must     │ Female patients must be postmenopausal or must     │
│ have had a bilateral oophorectomy or must have     │ have had a bilateral oophorectomy or must have     │
│ been surgically sterilized or hysterectomized at   │ been surgically sterilized or hysterectomized at   │
│ least 6 months prior to screening                  │ least 6 months prior to screening                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ To be eligible patients must fulfill the following │ To be eligible patients must fulfill the following │
│ criteria Patients on ongoing hypertensive therapy  │ criteria Patients on ongoing hypertensive therapy  │
│ must have a blood pressure ≥ 135/85 mm Hg but      │ must have a blood pressure ≥ 135/85 mm Hg but      │
│ lower than 170/105 mm Hg at baseline (Day -1) AND  │ lower than 170/105 mm Hg at baseline (Day -1) AND  │
│ patients must be on stable antihypertensive        │ patients must be on stable antihypertensive        │
│ medications for at least 8 weeks prior to baseline │ medications for at least 8 weeks prior to baseline │
│ (Day -1) Newly diagnosed hypertensive patients     │ (Day -1) Newly diagnosed hypertensive patients     │
│ must have a blood pressure ≥ 135/85 mm Hg but      │ must have a blood pressure ≥ 135/85 mm Hg but      │
│ lower than 170/105 mm Hg at baseline (Day -1)      │ lower than 170/105 mm Hg at baseline (Day -1)      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients must be on stable hypoglycemic            │ Patients must be on stable hypoglycemic            │
│ medications for at least 8 weeks prior to Visit 2  │ medications for at least 8 weeks prior to Visit 2  │
│ ( Day -1)                                          │ ( Day -1)                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients must be willing and medically able to     │ Patients must be willing and medically able to     │
│ discontinue all Angiotensin-converting enzyme      │ discontinue all Angiotensin-converting enzyme      │
│ inhibitor (ACEI) Angiotensin receptor blocker      │ inhibitor (ACEI) Angiotensin receptor blocker      │
│ (ARB) aldosterone receptor antagonist and          │ (ARB) aldosterone receptor antagonist and          │
│ potassium sparing diuretic medications for the     │ potassium sparing diuretic medications for the     │
│ duration of the study                              │ duration of the study                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Oral body temperature within the range 35 0-37 5   │ Oral body temperature within the range 35 0-37 5   │
│ °C                                                 │ °C                                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Able to provide written informed consent prior to  │ Able to provide written informed consent prior to  │
│ study participation                                │ study participation                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Able to communicate well with the investigator and │ Able to communicate well with the investigator and │
│ comply with the requirements of the study          │ comply with the requirements of the study          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe Hypertension Grade 3 WHO classification     │ Severe Hypertension Grade 3 WHO classification     │
│ (Mean Sitting Diastolic Blood Pressure (MSDBP) 110 │ (Mean Sitting Diastolic Blood Pressure (MSDBP) 110 │
│ mmHg and/or Mean Sitting Systolic Blood Pressure   │ mmHg and/or Mean Sitting Systolic Blood Pressure   │
│ MSSBP 180 mmHg)                                    │ MSSBP 180 mmHg)                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acetylsalicyclic acid (ASA) treatment >1g/day or   │ Acetylsalicyclic acid (ASA) treatment \>1g/day or  │
│ regular use of Non steroidal anti-inflammatory     │ regular use of Non steroidal anti-inflammatory     │
│ drug (NSAIDs)                                      │ drug (NSAIDs)                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Kidney disease not caused by diabetes or           │ Kidney disease not caused by diabetes or           │
│ hypertension                                       │ hypertension                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum potassium < 3 5 or > 5 1 mEq/L               │ Serum potassium \< 3 5 or \> 5 1 mEq/L             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ GFR < 40 ml/min/1 73m2 as measured by the MDRD     │ GFR \< 40 ml/min/1 73m2 as measured by the MDRD    │
│ formula                                            │ formula                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum albumin < 2 0mg/dL                           │ Serum albumin \< 2 0mg/dL                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of hypertensive encephalopathy or          │ History of hypertensive encephalopathy or          │
│ cerebrovascular accident at any time prior to      │ cerebrovascular accident at any time prior to      │
│ Visit1                                             │ Visit1                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current diagnosis of heart failure (New York Heart │ Current diagnosis of heart failure (New York Heart │
│ Association (NYHA) Class II-IV)                    │ Association (NYHA) Class II-IV)                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of myocardial infarction unstable angina   │ History of myocardial infarction unstable angina   │
│ pectoris coronary bypass surgery or any            │ pectoris coronary bypass surgery or any            │
│ percutaneous coronary intervention (PCI) during    │ percutaneous coronary intervention (PCI) during    │
│ the 6 months prior to Visit 1                      │ the 6 months prior to Visit 1                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Second or third degree heart block without a       │ Second or third degree heart block without a       │
│ pacemaker                                          │ pacemaker                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concurrent potentially life threatening arrhythmia │ Concurrent potentially life threatening arrhythmia │
│ or symptomatic arrhythmia                          │ or symptomatic arrhythmia                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinically significant valvular heart disease      │ Clinically significant valvular heart disease      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Type 1 diabetes mellitus                           │ Type 1 diabetes mellitus                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Uncontrolled Type II diabetes mellitus (Hemaglobin │ Uncontrolled Type II diabetes mellitus (Hemaglobin │
│ subtype A1C (HbA1C) >11 %)                         │ subtype A1C (HbA1C) \>11 %)                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of malignancy including leukemia and       │ History of malignancy including leukemia and       │
│ lymphoma (but not basal cell skin carcinoma)       │ lymphoma (but not basal cell skin carcinoma)       │
│ within the past five years                         │ within the past five years                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participation in any clinical investigation within │ Participation in any clinical investigation within │
│ 4 weeks prior to dosing or longer if required by   │ 4 weeks prior to dosing or longer if required by   │
│ local regulation                                   │ local regulation                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Donation or loss of 400 mL or more of blood within │ Donation or loss of 400 mL or more of blood within │
│ 8 weeks prior to dosing                            │ 8 weeks prior to dosing                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Significant illness within the two weeks prior to  │ Significant illness within the two weeks prior to  │
│ dosing                                             │ dosing                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any surgical or medical condition which might      │ Any surgical or medical condition which might      │
│ significantly alter the absorption distribution    │ significantly alter the absorption distribution    │
│ metabolism or excretion of study drugs including   │ metabolism or excretion of study drugs including   │
│ but not limited to any of the following            │ but not limited to any of the following            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of major gastrointestinal tract surgery    │ History of major gastrointestinal tract surgery    │
│ such as gastrectomy gastroenterostomy or bowel     │ such as gastrectomy gastroenterostomy or bowel     │
│ resection                                          │ resection                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ -Currently active or previously active             │ -Currently active or previously active             │
│ inflammatory bowel disease during the 12 months    │ inflammatory bowel disease during the 12 months    │
│ prior to Visit 1 Currently active gastritis        │ prior to Visit 1 Currently active gastritis        │
│ duodenal or gastric ulcers or                      │ duodenal or gastric ulcers or                      │
│ gastrointestinal/rectal bleeding during the 3      │ gastrointestinal/rectal bleeding during the 3      │
│ months prior to Visit 1                            │ months prior to Visit 1                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any history of pancreatic injury pancreatitis or   │ Any history of pancreatic injury pancreatitis or   │
│ evidence of impaired pancreatic function/injury as │ evidence of impaired pancreatic function/injury as │
│ indicated by abnormal lipase or amylase Evidence   │ indicated by abnormal lipase or amylase Evidence   │
│ of hepatic disease a history of hepatic            │ of hepatic disease a history of hepatic            │
│ encephalopathy a history of esophageal varices or  │ encephalopathy a history of esophageal varices or  │
│ a history of portocaval shunt                      │ a history of portocaval shunt                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current treatment with cholestyramine or           │ Current treatment with cholestyramine or           │
│ cholestipol resins                                 │ cholestipol resins                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of immunocompromise including a positive   │ History of immunocompromise including a positive   │
│ HIV test result                                    │ HIV test result                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of a positive Hepatitis B surface antigen  │ History of a positive Hepatitis B surface antigen  │
│ (HBsAg) or Hepatitis C test result                 │ (HBsAg) or Hepatitis C test result                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of drug or alcohol abuse within the 12     │ History of drug or alcohol abuse within the 12     │
│ months prior to dosing                             │ months prior to dosing                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Persons directly involved in the execution of this │ Persons directly involved in the execution of this │
│ protocol                                           │ protocol                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any condition that in the opinion of the           │ Any condition that in the opinion of the           │
│ investigator or the Novartis medical monitor would │ investigator or the Novartis medical monitor would │
│ jeopardize the evaluation of efficacy or safety    │ jeopardize the evaluation of efficacy or safety    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of noncompliance to medical regimens or    │ History of noncompliance to medical regimens or    │
│ unwillingness to comply with the study protocol    │ unwillingness to comply with the study protocol    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known or suspected contraindications to the study  │ Known or suspected contraindications to the study  │
│ medications including history of allergy to        │ medications including history of allergy to        │
│ Angiotensin converting enzyme (ACE) inhibitors     │ Angiotensin converting enzyme (ACE) inhibitors     │
│ and/or to thiazide diuretics or other sulfonamide  │ and/or to thiazide diuretics or other sulfonamide  │
│ derived drug                                       │ derived drug                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any surgical or medical condition which in the     │ Any surgical or medical condition which in the     │
│ opinion of the investigator may place the patient  │ opinion of the investigator may place the patient  │
│ at higher risk from his/her participation in the   │ at higher risk from his/her participation in the   │
│ study or is likely to prevent the patient from     │ study or is likely to prevent the patient from     │
│ complying with the requirements of the study or    │ complying with the requirements of the study or    │
│ completing the study                               │ completing the study                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of any prescription drug or over-the-counter   │ Use of any prescription drug or over-the-counter   │
│ (OTC) medication which is prohibited by the        │ (OTC) medication which is prohibited by the        │
│ protocol                                           │ protocol                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who previously participated in any        │ Patients who previously participated in any        │
│ Aliskiren study                                    │ Aliskiren study                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant or nursing woman                          │ Pregnant or nursing woman                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other protocol-defined inclusion/exclusion         │ Other protocol-defined inclusion/exclusion         │
│ criteria may apply                                 │ criteria may apply                                 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have maximum age of 80 Years │
├───────────────────────────────────┤
│ Must have minimum age of 30 Years │
╘═══════════════════════════════════╛